Generated by AI
Summary of Aug 13's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Jun 30's posts. Generated by AI.
Investors talking about XPH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
State Street SPDR S&P Pharmaceuticals ETF is a passively managed exchange-traded fund that provides targeted exposure to the U.S. pharmaceutical industry. The fund seeks to track the S&P Pharmaceuticals Select Industry Index, an equal-weighted benchmark that represents the pharmaceuticals segment of the broader U.S. equity market. Its portfolio includes a diversified mix of large, mid, and smaller pharmaceutical companies involved in drug development, manufacturing, commercialization, specialty therapeutics, and related healthcare services. The ETF is used by investors looking for sector-focused access to pharmaceutical businesses within a single listed fund structure. By concentrating on one healthcare subindustry, State Street SPDR S&P Pharmaceuticals ETF serves as a sector allocation tool and a way to participate in the performance of pharmaceutical companies across different therapeutic areas and business models.
The latest articles about XPH.
XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.
Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.
Active management and a philanthropic mission set Simplify apart, though State Street's lower costs and stronger recent returns appeal to passive investors.
Smart Beta ETF report for XPH